Australia markets closed

Apellis Pharmaceuticals, Inc. (APLS)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
43.54-1.47 (-3.27%)
At close: 1:00PM EST
43.54 0.00 (0.00%)
After hours: 01:01PM EST
Currency in USD

Valuation measures

Market cap (intra-day) 54.21B
Enterprise value 33.99B
Trailing P/E N/A
Forward P/E 1N/A
PEG ratio (5-yr expected) 1N/A
Price/sales (ttm)13.74
Price/book (mrq)N/A
Enterprise value/revenue 315.57
Enterprise value/EBITDA 7-8.02

Trading information

Stock price history

Beta (5Y monthly) 1.62
52-week change 3-7.64%
S&P500 52-week change 326.87%
52-week high 373.00
52-week low 327.50
50-day moving average 335.60
200-day moving average 348.96

Share statistics

Avg vol (3-month) 31.84M
Avg vol (10-day) 31.88M
Shares outstanding 597.36M
Implied shares outstanding 6N/A
Float 868.43M
% held by insiders 117.09%
% held by institutions 174.51%
Shares short (14 Nov 2021) 45.89M
Short ratio (14 Nov 2021) 45.18
Short % of float (14 Nov 2021) 49.73%
Short % of shares outstanding (14 Nov 2021) 46.75%
Shares short (prior month 14 Oct 2021) 45.72M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 3N/A
Trailing annual dividend yield 3N/A
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2020
Most-recent quarter (mrq)29 Sept 2021

Profitability

Profit margin -202.97%
Operating margin (ttm)-123.60%

Management effectiveness

Return on assets (ttm)-30.60%
Return on equity (ttm)-2,144.31%

Income statement

Revenue (ttm)256.27M
Revenue per share (ttm)3.19
Quarterly revenue growth (yoy)774.60%
Gross profit (ttm)-74.33M
EBITDA -315.48M
Net income avi to common (ttm)-520.16M
Diluted EPS (ttm)-6.47
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)430.31M
Total cash per share (mrq)4.93
Total debt (mrq)211.83M
Total debt/equity (mrq)N/A
Current ratio (mrq)5.05
Book value per share (mrq)-0.66

Cash flow statement

Operating cash flow (ttm)-308.65M
Levered free cash flow (ttm)-153.85M